WithdrawnPhase 1NCT04580238
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
Studying Reversible cerebral vasoconstriction syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alberta
- Principal Investigator
- Muzaffar M Siddiqui, MDUniversity of Alberta
- Intervention
- Botox 200 UNT Injection(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Division of Neurology, Grey Nuns Community Hospital, Edmonton, Alberta, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04580238 on ClinicalTrials.govOther trials for Reversible cerebral vasoconstriction syndrome
Additional recruiting or active studies for the same condition.
See all trials for Reversible cerebral vasoconstriction syndrome →